Global medicines and the future outlook
Newsletters and Deep Dive digital magazine
As Ozempic’s viral weight-loss fame skyrockets, shortages and counterfeit dangers loom, but is the industry ready to tackle the “trendification” of treatment?
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
TEST lorem ipsum dolor sit amet
Dear Readers,
Here is your starter for 10: What do AI, GLP-1s, and Taylor Swift have in common?
Well, in 2024, these powerhouse entities shared two key traits: soaring global demand and the ability to single-handedly boost a nation’s GDP. But while missing out on Era’s tour tickets may be disappointing, it’s not going to hurt your health.
In contrast, the meteoric rise of Ozempic from humble diabetes drug to pharmaceutical phenomenon has thrust the industry into uncharted territory, blending celebrity influence, social media trends, and off-label drug use, to create a perfect storm of demand, shortages, and easy opportunities for counterfeiters to take advantage of desperate patients.
And so, in this issue’s cover feature, we explore how a can transcend its original purpose and the real-world consequences of “trendification” in healthcare.
But we’re not just posing questions – we’re exploring solutions. Our features on communication strategies and data-driven storytelling offer practical tools for thriving in this new landscape. Plus, our timeline of Scottish medical innovations reminds us that adapting to change is part of our industry’s DNA.
From TikTok trends to time-honoured traditions of innovation, this issue spans the full spectrum of our evolving industry. As you delve into the complexities and opportunities discussed in this issue, I challenge you to think creatively. How do we turn potential disruptions into opportunities for meaningful innovation? And are we prepared to navigate this new landscape while staying true to our scientific roots?
Eloise McLennan
Deep Dive editor
A history of: Scottish medical innovation
The Ozempic dilemma: Balancing demand, supply, and patient safety in a viral GLP-1 World
Five top tips for developing a communication strategy
Accelerating pharma marketing: Mastering content velocity for maximum impact
The Big Interview: Measuring the impact of medical affairs
ChatGPT will write your brand story if you don’t (and four more AI insights from Future Pharma)
Beyond the science: Crafting compelling stories with data-driven medical communications
Assessing the global applicability of the UK’s ‘Netflix’-style subscription model for antibiotics
Supercharge your pharma insights: Sign up to pharmaphorum's newsletter for daily updates, weekly roundups, and in-depth analysis across all industry sectors.
Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens.
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
Imagine the difference it would make if everyone in your organisation had firsthand experience of living with one of the conditions you help treat. What insights would you gain?
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and